S-e Lee

Seoul St Mary's Hospital
Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.

Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.

Journal: Bone marrow transplantation

Published: May 09, 2016

Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia.

Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia.

Journal: Bone marrow transplantation

Published: January 05, 2016

Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.

Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.

Journal: Bone marrow transplantation

Published: May 12, 2015

MyD88 in donor bone marrow cells is critical for protection from acute intestinal graft-vs.-host disease.

MyD88 in donor bone marrow cells is critical for protection from acute intestinal graft-vs.-host disease.

Journal: Mucosal immunology

Published: January 17, 2015

Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

Journal: Bone marrow transplantation

Published: August 27, 2014

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.

Journal: Bone marrow transplantation

Published: March 03, 2014

PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL.

PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL.

Journal: Bone marrow transplantation

Published: September 17, 2013

Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA?

Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA?

Journal: Bone marrow transplantation

Published: March 19, 2013

Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure.

Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure.

Journal: Bone marrow transplantation

Published: November 07, 2012

Risk and prognostic factors for acute GVHD based on NIH consensus criteria.

Risk and prognostic factors for acute GVHD based on NIH consensus criteria.

Journal: Bone marrow transplantation

Published: September 25, 2012

Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal: Leukemia

Published: June 19, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026